FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL. (June 2017) - Gressin, R.; Daguindau, N.; Tempescul, A.; Moreau, A.; Carras, S.; Cartron, G.; Schmitt, A.; Houot, R.; Dartigeas, C.; Pignon, J.; Corm, S.; Bannos, A.; et al.